Kamran Roudini

Kamran Roudini

Auto-generated profile, based on publicly available information

Kamran Roudini

Department of Internal Medicine, Hematology and Medical Oncology Ward, Cancer research center, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2023 in Pathology - Research and Practice
Verified
Journal Article
Closed access
HMHossein Mehralizadeh
Hossein Mehralizadeh
ANAhmad Nazari
Ahmad Nazari
FOFarshid Oruji
Farshid Oruji
MRMinoo Roostaie
Minoo Roostaie
GHGhazaleh Hosseininozari
Ghazaleh Hosseininozari
KRKamran Roudini
Kamran Roudini

15 February 2023 in JMIR Cancer
Verified
Journal Article
Open access
SASeyed Mohammad Ayyoubzadeh
Seyed Mohammad Ayyoubzadeh
TBTayebeh Baniasadi
Tayebeh Baniasadi
MSMohammad Shirkhoda
Mohammad Shirkhoda
SKSharareh Rostam Niakan Kalhori
Sharareh Rostam Niakan Kalhori
NMniloofar mohammadzadeh
niloofar mohammadzadeh
AJAmirmohsen Jalaeefar
Amirmohsen Jalaeefar
Background: Patients with colorectal cancer who undergo surgery face many postoperative problems. These problems include the risk of relapse, side effects, and long-term complications. Objective: This study sought to design and develop a remote monitoring system as a technological solution for the postdischarge care of these patients. Methods: This research was conducted in 3 main steps: system feature extraction, system design, and evaluation. After feature extraction from a systematic review, the necessary features were defined by 18 clinical experts in Iran. In the next step, the architecture of the system was designed based on the requirements; the software and hardware parts of the system were embedded in the architecture, then the software system components were drawn using the unified modeling language diagrams, and the details of software system implementation were identified. Regarding the hardware design, different accessible hardware modules were evaluated, and suitable ones were selected. Finally, the usability of the system was evaluated by demonstrating it over a Skype virtual meeting session and using Nilsen’s usability principles. Results: A total of 21 mandatory features in 5 main categories, including patient information registration, periodic monitoring of health parameters, education, reminders, and assessments, were defined and validated for the system. The software was developed using an ASP.Net core backend, a Microsoft SQL Server database, and an Ionic frontend alongside the Angular framework, to build an Android app. The user roles of the system included 3 roles: physicians, patients, and the system administrator. The hardware was designed to contain an Esp8266 as the Internet of Things module, an MLX90614 infrared temperature sensor, and the Maxim Integrated MAX30101 sensor for sensing the heartbeat. The hardware was designed in the shape of a wristband device using SolidWorks 2020 and printed using a 3D printer. The firmware of the hardware was developed in Arduino with the capability of firmware over the air. In evaluating the software system from the perspective of usability, the system received an average score of 3.8 out of 5 from 4 evaluators. Conclusions: Sensor-based telemonitoring systems for patients with colorectal cancer after surgery are possible solutions that can make the process automatic for patients and caregivers. The apps for remote colorectal patient monitoring could be designed to be useful; however, more research regarding the developed system’s implementation in clinic settings and hospitals is required to understand the probable barriers and limitations.

15 March 2024 in Cardio-Oncology
Verified
Journal Article
Open access
PDF file
AAAzin Alizadehasl
Azin Alizadehasl
MMMina Mohseni
Mina Mohseni
KRKamran Roudini
Kamran Roudini
PFParisa Firoozbakhsh
Parisa Firoozbakhsh
Background: Trastuzumab is one of the most effective treatments in HER-2 positive breast cancer patients. However, it is associated with development of cardiomyopathy/heart failure (HF) which is often a limiting side effect and associated with overall adverse outcomes. As a result, patients with pre-existing LV systolic dysfunction (LVSD) are often excluded from receiving anti-HER-2 therapy, which may lead to less effective cancer treatment and worse prognosis. Objectives: The current study aims to evaluate the safety of trastuzumab in patients with HER-2 positive breast cancer and pre-existing LVSD. Methods: In this retrospective cohort study, 36 consecutive patients at a single center in Iran with HER-2 positive breast cancer with asymptomatic mild LVSD with LVEF 40–53% without heart failure symptoms and those who were closely followed in the Cardio-Oncology clinic before initiating the treatment and then every two cycles of trastuzumab were included. As per the program standard protocol they received a beta-blocker (carvedilol) and ACE-I (Lisinopril), up to the maximum tolerated dose, if there were no contraindications. Patients underwent routine echocardiography with global longitudinal strain (GLS) assessment every 3 months per guideline recommendations and were followed up 6 months after the end of treatment. Primary composite outcomes included myocardial infarction (MI), cardiac arrhythmia, heart failure(HF) symptoms and cardiovascular death. Secondary outcome was ≥ 10% reduction in LVEF or ≥ 15% reduction in GLS compared to baseline. If the LVEF decreased below 40%, the treatment was temporarily interrupted for one or two cycles, and spironolactone was added to the patient’s treatment. If the LVEF improved ≥ 40%, trastuzumab was rechallenged. Data analysis was performed using IBM SPSS Statistics 24.0. Software. Patients’ characteristics were reported using descriptive statistics, and its association with drop in LVEF or GLS was assessed using Pearson chi-square or Mann-Whitney U test. A p-value of less than 0.05 was considered significant. Results: Thirty-six patients were included in the study. Primary composite outcome was noted in 1(2.8%) patient. LVEF reduction of ≥ 10% occurred in 6(16.7%) of the patients, and a GLS reduction of more than 15% was detected in 4 (11.1%) of the patients. There was a significant association between a ≥ 10% reduction in LVEF and baseline systolic blood pressure (P-value: 0.04). LVEF reduction below 40% was observed in 3 (8.3%) patients, where trastuzumab was interrupted. All of these three patients had obesity (Median BMI 34.11, IQR 9.12) and uncontrolled HTN, and one of them had symptoms of heart failure (NYHA class II), for whom the trastuzumab treatment was discontinued. Among two patients, after the temporary interruption of trastuzumab, and addition of spironolactone, LVEF improved to above 40%, and the treatment was restarted with close cardiac monitoring; therefore, they could complete the entire one-year treatment period. Conclusions: Treatment with trastuzumab seems to be safe in patients with pre-existing LVSD (LVEF = 40–53%). Such high-risk patients should be strictly monitored and cardiovascular risk factors, such as HTN should be regulated.

14 November 2025 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
MMMehrzad Mirzania
Mehrzad Mirzania
AKAhmad Khajeh-Mehrizi
Ahmad Khajeh-Mehrizi
TYTahereh Yavari
Tahereh Yavari
SNSeyed Reza Safaei Nodehi
Seyed Reza Safaei Nodehi
KRKamran Roudini
Kamran Roudini
PTPeyman Tayyari
Peyman Tayyari
Background: Acute myeloid leukemia (AML) presents significant treatment challenges, particularly in refractory or relapsed (R/R) cases. This study evaluates the efficacy and outcomes of the salvage chemotherapy regimen containing etoposide 100 mg/m 2 and mitoxantrone 10 mg/m 2 , both on days 1–5 (EM) in non-M3 AML patients. Methods: In a retrospective cohort study, data from 2011 to 2021 were analyzed for adult non-M3 AML patients in a tertiary referral center. Patients who underwent EM salvage chemotherapy after induction failure were included. Exclusion criteria were patients who died during induction, remission with induction, or ineligible for salvage chemotherapy. Results: Out of 449 non-M3 AML patients, 41 (9.1%) received the EM regimen. Of these, 19 (46.3%) showed no response, 5 (12.2%) achieved partial remission (PR), and 17 (41.5%) attained complete remission (CR). The median overall survival (OS) for all patients was 6 months (95% CI 2.3–9.6), with 12, 24, and 36-month OS rates of 31%, 23%, and 15%, respectively. Patients achieving CR or PR had significantly better outcomes compared to refractory patients. Patients who did not receive hematopoietic stem cell transplantation (HSCT) had a median OS of 7 months, while it was not reached for those who did undergo HSCT. At 36 months, the OS rate was significantly higher in patients who underwent HSCT than in those who did not (71.4% vs. 8.3% P = 0.001). Conclusions: The EM regimen offers a potential pathway to remission for R/R non-M3 AML patients. However, the outcomes are heavily influenced by patient-specific factors and subsequent treatment strategies such as HSCT.

9 February 2024 in Jundishapur Journal of Microbiology
Verified
Journal Article
Open access
PDF file
MSMohammadreza Salehi
Mohammadreza Salehi
NSNafiseh Shahrbaf
Nafiseh Shahrbaf
FSFarhad Shahi
Farhad Shahi
SKSadegh Khodavaisy
Sadegh Khodavaisy
SMSeyed Ali Dehghan Manshadi
Seyed Ali Dehghan Manshadi
HSHasti Kamali Sarvestani
Hasti Kamali Sarvestani
Background: The incidence of invasive aspergillosis (IA) has significantly increased in recent decades. In patients with hematologic malignancies (HM), IA is associated with higher mortality rates. Objectives: This study aimed to assess the clinical features of IA in patients with HM. Methods: In this retrospective study, we used the hospital information system (HIS) database to extract clinical and paraclinical characteristics of patients with various HMs who received a diagnosis of probable or proven IA during their hospitalization at Imam Khomeini Hospital Complex in Tehran, Iran, between March 2018 and March 2022. Results: After evaluating 350 patients with HM, 51 patients with IA (14.6%) were identified, of whom 40 cases (78.4%) were probable and 11 (21.6%) were proven. Among these, 34 individuals (66.7%) were male. The most common symptoms were fever (n = 23, 62.7%), cough (n = 20, 39.2%), and fever that did not respond to antibiotic therapy (n = 16, 31.4%). The most prevalent malignancies were AML (n = 28, 54.9%), ALL (n = 16, 31.4%), and lymphoma (n = 7, 13.7%). Out of the 51 patients with HM and IA, 48 (94.1%) had abnormal findings on chest CT scans, with the majority (n = 31, 72.1%) showing a nodule with a halo sign. Aspergillus flavus (n = 19/24, 79.2%) was the most commonly isolated species. Initially, patients received liposomal amphotericin B or caspofungin as empiric antifungal therapy, which was then switched to voriconazole once the diagnosis of IA was probable or proven. Eight patients (15.6%) died. Conclusions: Patients with HM presenting with fever and cough should undergo close monitoring for IA. A higher incidence of IA is observed in AML patients, and voriconazole could be considered as antifungal prophylaxis in HM patients. A. flavus is likely the most frequent cause of IA in Iranian patients with HM.

20 June 2022 in Anesthesiology and Pain Medicine
Verified
Journal Article
Open access
PDF file
RARasoul Azarfarin
Rasoul Azarfarin
MZMohsen Ziyaeifard
Mohsen Ziyaeifard
AAAzin Alizadehasl
Azin Alizadehasl
KRKamran Roudini
Kamran Roudini
FHFatemehshima Hadipourzadeh
Fatemehshima Hadipourzadeh
JJJavad Jamalian
Javad Jamalian
Introduction: One of the conditions leading to hemolysis in patients with artificial metallic heart valves is valvular dysfunction. In case of symptomatic hemolysis, a blood transfusion may be needed along with standard treatments. Inattention to the differential diagnosis of hemolysis and making decisions based on causes that are more obvious can lead to incorrect approaches. Case Presentation: In this case report, we presented a case with a previously undiagnosed rare blood group (positive antibody anti-E, anti-c, anti-Kell), undergoing reoperation of mitral valve replacement (MVR), who developed severe hemolysis and subsequent acute renal failure secondary to incompatible blood transfusion and required hemodialysis. Conclusions: In this patient, hemolysis was solely attributed to mitral valve dysfunction. By timely diagnosis of the subtype of her blood group and appropriate decision-making during surgery, adverse blood transfusion outcomes were prevented.